You Searched For "Takeda" and got 20 results
Sort By:
1 min read
A bidding war is brewing over $50 billion drugmaker Shire
Shire is known for making ADHD medicine, like Adderall and Vyvanse, and its focus on rare diseases …
Lydia Ramsey
4 mins read
Three-week lockdown reasonable starting point to fight coronavirus in India: former White House official
A three-week lockdown is a reasonable starting point to contain the coronavirus pandemic in a coun…
PTI
1 min read
Raman Rao to join Hilleman Labs as CEO
New Delhi, Jan 27 () Hilleman Laboratories, a joint venture between pharma company MSD and Wellcome…
PTI
1 min read
Granules Pharmaceuticals, Inc gets USFDA nod for Colchicine tablets
"The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (…
PTI
3 mins read
Meet the bankers involved in what could be a $64 billion takeover of the maker of Adderall
Evercore's team is made up of Will Hiltz, John Honts, and Julian Oakley. Hiltz is a New York-based …
Matt Turner,Lydia Ramsey
1 min read
Indoco gets USFDA nod for Febuxostat tablets
New Delhi, Dec 31 () Indoco Remedies on Tuesday said it has got final approval from the US health r…
PTI
2 mins read
10 things you need to know before the opening bell
Japan's Takeda seals $62 billion takeover of Adderall maker Shire. The deal will pay Shire investor…
Jonathan Garber
2 mins read
Healthcare dealmaking just hit an all-time record of almost $400 billion - here are some of the year's biggest mergers
The most recent healthcare deal, announced on Tuesday, was medical device company Boston Scientific…
Zachary Tracer
4 mins read
Pharmaceutical dealmaking is starting to heat up - here's where it's headed
Specialty pharma dealmaking fell off abruptly in 2017 with just $7 billion in deals, the lowest sin…
Lydia Ramsey
3 mins read
A Japanese drug giant and a tiny New York biotech are teaming up in an unprecedented way
Dr. Jeremy Levin, Ovid's CEO, told Business Insider that this was the first time he'd seen an arran…
Lydia Ramsey
2 mins read
Men who have recovered from the coronavirus may be better plasma donors than women
Men tend to get more severe cases of coronavirus, so male survivors generally have more antibodies …
Anna Medaris Miller
1 min read
What you need to know on Wall Street today
Allergan then confirmed it was "in the early stages of considering a possible offer" for Shire. Tha…
Matt Turner
2 mins read
MIT has a new AI model that can detect asymptomatic COVID-19 patients just by the using the sound of their coughs recorded over phone calls
MIT’s new AI model detects COVID-19 patients who may be asymptomatic — just by using coughs recorde…
6 mins read
The FDA has authorized convalescent plasma treatment for coronavirus patients — but some scientists worry it's too soon
The FDA just authorized convalescent plasma as an emergency treatment for COVID-19. It could preven…
Aria Bendix
1 min read
MORGAN STANLEY: These 7 pharma companies will be critical to fighting infectious diseases brought on by climate change
By 2050, between 383 million and 725 million more individuals may be exposed to diseases that are s…
Ben Winck
1 min read
It looks like a key Valeant deal might be falling apart, and now the stock is tanking
The embattled pharma company had been in talks to sell the unit to Japan's Takeda for $10 billion.V…
Rachael Levy
2 mins read
STOCKS SLIP: Here's what you need to know
The S&P 500 and Dow Jones indexes both found themselves in the red, while the tech-heavy Nasdaq…
Bob Bryan
2 mins read
10 things you need to know before the opening bell
BlackRock's $1.8 trillion bond chief explains how millennials are spearheading an economic revoluti…
Jonathan Garber
2 mins read
A new drug to treat lung cancer just got approved
The drug, made by Japanese drug giant Takeda Pharmaceuticals, is called brigatinib. It's a type of …
Lydia Ramsey
3 mins read
There's still a lot of uncertainty about what Trump will do about drug prices - here's what drugmakers are doing in the meantime
Eli Lilly CEO David Ricks said that Trump's drug pricing policy didn't get discussed detail in the …